Mohannad Natheef AbuHaweeleh, Lubna Therachiyil, Kirti S Prabhu, Omar M Khan, Shahab Uddin
{"title":"SKP2 E3 ligase in urological malignancies: a critical regulator of the cell cycle and therapeutic target.","authors":"Mohannad Natheef AbuHaweeleh, Lubna Therachiyil, Kirti S Prabhu, Omar M Khan, Shahab Uddin","doi":"10.1080/15384101.2025.2526211","DOIUrl":null,"url":null,"abstract":"<p><p>SKP2, an E3 ubiquitin ligase component of the SCF complex, plays a critical role in cell cycle regulation by targeting key inhibitors like p27, p21, and p57 for degradation, thereby promoting G1-S transition. Its overexpression is strongly associated with urological malignancies, including prostate, bladder, and kidney cancers, where it correlates with aggressive disease and poor prognosis. SKP2 drives tumor progression, via enhancing cancer cell proliferation, invasion, and metastasis. Targeting SKP2 through small molecule inhibitors or combination therapies holds promise for cancer treatment. However, challenges remain, including understanding its role in cancer stem cells, metastasis, and treatment resistance. Continued research is essential to harness SKP2's potential as a therapeutic target and biomarker for personalized medicine in urological cancers.</p>","PeriodicalId":9686,"journal":{"name":"Cell Cycle","volume":" ","pages":"1-15"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Cycle","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/15384101.2025.2526211","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
SKP2, an E3 ubiquitin ligase component of the SCF complex, plays a critical role in cell cycle regulation by targeting key inhibitors like p27, p21, and p57 for degradation, thereby promoting G1-S transition. Its overexpression is strongly associated with urological malignancies, including prostate, bladder, and kidney cancers, where it correlates with aggressive disease and poor prognosis. SKP2 drives tumor progression, via enhancing cancer cell proliferation, invasion, and metastasis. Targeting SKP2 through small molecule inhibitors or combination therapies holds promise for cancer treatment. However, challenges remain, including understanding its role in cancer stem cells, metastasis, and treatment resistance. Continued research is essential to harness SKP2's potential as a therapeutic target and biomarker for personalized medicine in urological cancers.
期刊介绍：
Cell Cycle is a bi-weekly peer-reviewed journal of high priority research from all areas of cell biology. Cell Cycle covers all topics from yeast to man, from DNA to function, from development to aging, from stem cells to cell senescence, from metabolism to cell death, from cancer to neurobiology, from molecular biology to therapeutics. Our goal is fast publication of outstanding research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
